




RealRate

PHARMACEUTICAL 2022

United Therapeutics Corp
Rank 128 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of United Therapeutics Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points. The greatest weakness of United Therapeutics Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 359%, being 84% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,323,600
Cost of Goods Sold	122,500
Intangible Assets	0
Liabilities, Current	305,400
Liabilities, Non-Current	104,800
Other Assets	2,064,600
Other Compr. Net Income	-8,800
Other Expenses	585,100
Other Liabilities	800,000
Other Net Income	38,000
Other Revenues	1,685,500
Property and Equipment	780,900
Research and Development	540,100
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	5,169,100
Liabilities	1,210,200
Expenses	1,247,700
Revenues	1,685,500
Stockholders Equity	3,958,900
Net Income	475,800
Comprehensive Net Income	471,400
BaseVar	4,679,650
ECR before LimitedLiability	285%
Economic Capital Ratio	359%